A Phase 3 Efficacy Study Of Dimebon In Patients With Moderate To Severe Alzheimer's Disease

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00912288
Recruitment Status : Terminated (See termination reason in detailed description.)
First Posted : June 3, 2009
Results First Posted : October 2, 2012
Last Update Posted : October 2, 2012
Medivation, Inc.
Information provided by (Responsible Party):

June 1, 2009
June 3, 2009
July 30, 2012
October 2, 2012
October 2, 2012
September 2009
August 2010   (Final data collection date for primary outcome measure)
  • Change From Baseline in the Severe Impairment Battery (SIB) Score at Week 26 [ Time Frame: Baseline, Week 26 ]
    SIB developed for evaluation of cognitive function in participants, who demented to a degree that they cannot complete conventional neuropsychological testing. Test items consisted of simple, one-step commands presented with gestural cues and instructions that were repeated if necessary. SIB test consisted of 51-item scale, divided into 9 subscales: social interaction (0-6), memory (0-14), orientation (0-6), language (0-46), attention (0-6), praxis(0-8), visuospatial ability(0-8), construction(0-4), orienting to name(0-2). Total possible score:0-100; lower score = greater cognitive impairment.
  • Change From Baseline in the Alzheimer's Disease Cooperative Study - Activities of Daily Living (Severe) (ADCS-ADLsev) Score at Week 26 [ Time Frame: Baseline, Week 26 ]
    ADCS-ADLsev: 19-item scale measures basic and instrumental abilities in participant population and had good metric properties and reliability in detecting change. Individual score range: 0 to 5 for telephone, 0 to 4 for dressing, watch television, get around outside home, 0 to 3 for eating, walking, toilet, bathing, grooming, conversation/small talk, clear dishes, find personal belongings, obtain beverages, dispose of garbage, left on own, 0 to 1 for run water from and turn off faucet to wash hands, turn on and off light. Total score range: 0 to 54 lower scores=greater functional impairment.
  • Change from baseline in the Severe Impairment Battery [ Time Frame: 26 weeks ]
  • Change from Baseline in ADCS-Activities of Daily Living (severe) [ Time Frame: 26 weeks ]
Complete list of historical versions of study NCT00912288 on Archive Site
  • Change From Baseline in the Neuropsychiatric Inventory (NPI) Total Score at Week 26 [ Time Frame: Baseline, Week 26 ]
    NPI:12-domain caregiver assessment of behavioral disturbances occurring in dementia: delusions, hallucinations, agitation/aggression, depression/dysphoria, anxiety, elation/euphoria, apathy/indifference, disinhibition, irritability/lability, motor disturbance, appetite/eating, nighttime behavior. Severity(1=Mild to 3=Severe),frequency(1=occasionally to 4=very frequently) scales recorded for each domain; frequency*severity=each domain score(range 0-12). Total score=sum of each domain score(range 0-144);higher score=greater behavioral disturbances;negative change score from baseline=improvement.
  • Sum of the Delusions and Hallucinations Sub-domain Scores of the NPI [ Time Frame: Week 26 ]
    NPI is a 12-domain caregiver assessment of behavioral disturbances occurring in dementia. Severity (1=Mild to 3=Severe) and frequency (1=occasionally to 4=very frequently) scales were recorded separately for each domain and their product gives individual domain score (range 0-12). Sum of delusions and hallucinations sub-domain scores of NPI was calculated as a measure of Alzheimer's Disease (AD) related psychosis. Total possible score range: 0-24 with higher score indicating greater behavioral disturbances.
  • Change From Baseline in the Mini-Mental State Examination (MMSE) Score at Week 26 [ Time Frame: Baseline, Week 26 ]
    MMSE measured general cognitive functioning: orientation, memory, attention, concentration, naming, repetition, comprehension, and ability to create a sentence and to copy two intersecting polygons. Total score derived from sub-scores; total ranged from 0 to 30, higher score indicates better cognitive state.
  • Clinician's Interview-Based Impression of Change Plus Caregiver Input (CIBIC-plus) Scores [ Time Frame: Week 26 ]
    Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change (ADCS-CGIC) version of CIBIC-Plus was used to assess participant's overall disease severity. The corresponding baseline assessment rated participant on 7-point scale: (1) extremely severe AD to (7) no symptoms of AD. Overall impression of change from baseline was rated on a 7-point scale: 1=marked improvement; 2=moderate improvement; 3=minimal improvement; 4=no change; 5=minimal worsening; 6=moderate worsening; 7=marked worsening; all assessments are relative to baseline. Higher score = worsening of global function.
  • Resource Utilization in Dementia-Lite Version (RUD-Lite) [ Time Frame: Baseline, Weeks 12, 18, 26 ]
    RUD Lite: instrument used to assess amount of both formal and informal resources used by demented participants and primary caregiver. It was completed by caregivers and compiles data on following resources: use of social services, frequency and duration of hospitalizations, all contacts with health care professionals, participant living accommodations, amount of time the caregiver spends giving care and the impact of care giving on the caregiver's job. Overall cost of care was evaluated to quantify resources utilized.
  • Euro Quality of Life - 5 Domain (EQ-5D) Assessment [ Time Frame: Baseline, Weeks 12, 26 ]
    EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single utility score. Health State Profile component assesses level of current health for 5 domains: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression; 1 indicates better health state (no problems); 3 indicates worst health state. Total possible score ranged from 5 to 15; lower score indicated a better health state.
  • Population Pharmacokinetic (PK) Analysis [ Time Frame: Pre-dose, 0.5 to 1.5 hours, 2.5 to 3.5 hours post-dose at Week 12 ]
    Data for this Outcome Measure are not reported here because the analysis population includes participants who were not enrolled in this study. is designed for reporting results from only those participants who were enrolled in the study and described in the Participant Flow and Baseline Characteristics modules.
  • Number of Participants With Adverse Events (AEs) [ Time Frame: Baseline up to Week 30 (follow-up) ]
    Any untoward medical occurrence (including clinially important changes in clinical safety laboratory assessments, electrocardiograms and vital signs) in a participant who received study treatment was considered an AE without regard to possibility of causal relationship.
  • Change from baseline in the Neuropsychiatric Inventory [ Time Frame: 26 weeks ]
  • Change from baseline in the Clinician's Global Impression of Change (plus caregiver input) [ Time Frame: 26 weeks ]
  • Change from baseline in Mini-mental State Exam [ Time Frame: 26 weeks ]
  • Change from baseline Resource Utilization in Dementia [ Time Frame: 26 weeks ]
  • Change from baseline in EuroQoL - 5 Domain assessment [ Time Frame: 26 weeks ]
  • Safety and Tolerability including adverse events and summary of clinically important changes in clinical safety laboratory assessments, electrocardiograms, and vital signs [ Time Frame: 26 weeks ]
Not Provided
Not Provided
A Phase 3 Efficacy Study Of Dimebon In Patients With Moderate To Severe Alzheimer's Disease
A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled 26-Week Trial To Evaluate The Efficacy And Safety Of Dimebon In Patients With Moderate-To-Severe Alzheimer's Disease
No Dimebon clinical data exist yet in patients with disease that has advanced to the moderate-to-severe stage. Therefore, this study evaluates the safety and efficacy of Dimebon in patients with moderate-to-severe AD who are receiving existing background therapy with memantine.
This study was terminated on May 7, 2010 due to modification of the dimebon development plan following the lack of demonstration of efficacy in the completed DIM14 (CONNECTION) Study. The study was not terminated due to any safety findings. Dimebon has been well-tolerated in clinical trials. Demonstration of efficacy for dimebon in Alzheimer's disease is pending completion of the ongoing DIM18 (CONCERT) Study.
Phase 3
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Alzheimer Disease
  • Drug: Dimebon 20 mg po TID
    Dimebon 10 mg po TID for 1 week followed by Dimebon 20 mg TID for 25 weeks
    Other Names:
    • PF-01913539
    • Latrepirdine Dihydrochloride
  • Drug: Placebo po TID
    Placebo (matched to Dimebon) po for 26 weeks
  • Experimental: Dimebon
    Intervention: Drug: Dimebon 20 mg po TID
  • Placebo Comparator: Placebo
    Intervention: Drug: Placebo po TID
Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
August 2010
August 2010   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Are men and women ≥ 50 years of age with a diagnosis of Alzheimers disease.
  • Have a Mini-Mental State Exam between 5 and 14 inclusive.
  • Have been taking the medication memantine (ie., Namenda) for at least six months prior to this study.
  • Must have a caregiver who assists the patient at least five days per week for at least three hours per day, who can accompany patient to study visits, and who has an intimate knowledge of the patient's health states and personal care.

Exclusion Criteria:

  • Have taken medicines for Alzheimers disease other than memantine (e.g., donepezil, rivastigmine, galantamine, tacrine) within 2 months prior to this study.
  • Dementia other than Alzheimers disease.
  • Any medical condition or reason that interferes with the ability of the patient to participate in or complete the trial or places the patient at undue risk, as judged by the study doctor.
Sexes Eligible for Study: All
50 Years and older   (Adult, Older Adult)
Contact information is only displayed when the study is recruiting subjects
Canada,   Germany,   Hungary,   Portugal,   Slovakia,   Spain,   Turkey,   United States
Not Provided
Not Provided
Medivation, Inc.
Study Director: Pfizer Call Center Pfizer
August 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP